These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

566 related items for PubMed ID: 30168880

  • 1. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M, Komine M, Hioki T, Kamiya K, Sugai J, Ohtsuki M.
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [Abstract] [Full Text] [Related]

  • 2. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O.
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [Abstract] [Full Text] [Related]

  • 3. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J.
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [Abstract] [Full Text] [Related]

  • 4. Apremilast in psoriasis - a prospective real-world study.
    Vujic I, Herman R, Sanlorenzo M, Posch C, Monshi B, Rappersberger K, Richter L.
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):254-259. PubMed ID: 28925560
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L, Bagel J, Lebwohl M, Jackson JM, Chen R, Goncalves J, Levi E, Duffin KC.
    J Drugs Dermatol; 2018 Feb 01; 17(2):221-228. PubMed ID: 29462231
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V.
    J Eur Acad Dermatol Venereol; 2018 Mar 01; 32(3):397-402. PubMed ID: 29220542
    [Abstract] [Full Text] [Related]

  • 7. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R, Alikhan A.
    Expert Rev Clin Pharmacol; 2017 Apr 01; 10(4):349-360. PubMed ID: 28276777
    [Abstract] [Full Text] [Related]

  • 8. Drug survival of apremilast in a real-world setting.
    Kishimoto M, Komine M, Kamiya K, Sugai J, Ohtsuki M.
    J Dermatol; 2019 Jul 01; 46(7):615-617. PubMed ID: 31180150
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG.
    J Drugs Dermatol; 2013 Aug 01; 12(8):888-97. PubMed ID: 23986162
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D.
    J Eur Acad Dermatol Venereol; 2018 Jul 01; 32(7):1173-1179. PubMed ID: 29388335
    [Abstract] [Full Text] [Related]

  • 12. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S.
    J Rheumatol; 2015 Mar 01; 42(3):479-88. PubMed ID: 25593233
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
    Ighani A, Georgakopoulos JR, Zhou LL, Walsh S, Shear N, Yeung J.
    J Cutan Med Surg; 2018 Mar 01; 22(3):290-296. PubMed ID: 29373924
    [Abstract] [Full Text] [Related]

  • 14. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC, McNamee KE, McCann FE.
    Drug Des Devel Ther; 2013 Mar 01; 7():201-10. PubMed ID: 23569359
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L, Del Duca E, Romanelli M, Saraceno R, Chimenti S, Chiricozzi A.
    Expert Opin Drug Metab Toxicol; 2016 Sep 01; 12(9):1121-8. PubMed ID: 27376729
    [Abstract] [Full Text] [Related]

  • 16. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Crowley J, Thaçi D, Joly P, Peris K, Papp KA, Goncalves J, Day RM, Chen R, Shah K, Ferrándiz C, Cather JC.
    J Am Acad Dermatol; 2017 Aug 01; 77(2):310-317.e1. PubMed ID: 28416342
    [Abstract] [Full Text] [Related]

  • 17. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
    AbuHilal M, Walsh S, Shear N.
    J Cutan Med Surg; 2016 Jul 01; 20(4):313-6. PubMed ID: 26848145
    [Abstract] [Full Text] [Related]

  • 18. Real-World Experience With Apremilast in Treating Psoriasis.
    Mayba JN, Gooderham MJ.
    J Cutan Med Surg; 2017 Jul 01; 21(2):145-151. PubMed ID: 27846617
    [Abstract] [Full Text] [Related]

  • 19. Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis.
    Ohata C, Ohyama B, Kuwahara F, Katayama E, Nakama T.
    J Dermatolog Treat; 2019 Jun 01; 30(4):383-386. PubMed ID: 30221571
    [Abstract] [Full Text] [Related]

  • 20. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S, Kavanaugh A.
    Expert Opin Drug Saf; 2015 Jun 01; 14(6):979-85. PubMed ID: 25827658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.